Freeport-McMoRan Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? Freeport-McMoRan Inc trades at $72.58 (market cap $103.19B), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: Freeport-McMoRan Inc is far larger — about 4.1× Roivant Sciences Ltd. Common Shares's market cap, and Freeport-McMoRan Inc pays a 0.83% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 69 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| FCX | ROIV | |
|---|---|---|
Market Cap | $103.19B | $25.09B |
Volume | 11,744,911 | 5,738,571 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $41.81 |
52-Week Low | $38.65 | $16.04 |
Typical Hold Time | 69 Days | 0 Days |
Enterprise Value | $109.47B | $21.36B |
Dividend Yield | 0.83% | — |
Signals from Pluang's Aura AI — not financial advice
FCX trades at $71.13, down 1.98% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $72.27. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Strong operating cash flow of $5.61 billion in 2025 supports ongoing expansion projects amid favorable copper demand trends.
The outlook for FCX is positive, driven by robust copper demand from AI and data center growth, but risks include rising production costs and a legal investigation. Wall Street sentiment is bullish with 61% buy ratings, though the stock faces near-term resistance at $72.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →